Download
s00432-020-03334-3.pdf 714,83KB
WeightNameValue
1000 Titel
  • Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide
1000 Autor/in
  1. Berger, Kerstin |
  2. Turowski, Bernd |
  3. Felsberg, Jörg |
  4. Malzkorn, Bastian |
  5. Reifenberger, Guido |
  6. Steiger, Hans-Jakob |
  7. Budach, Wilfried |
  8. Haussmann, Jan |
  9. Knipps, Johannes |
  10. Rapp, Marion |
  11. Hänggi, Daniel |
  12. Sabel, Michael |
  13. Mijderwijk, Hendrik-Jan |
  14. Kamp, Marcel |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-08-03
1000 Erschienen in
1000 Quellenangabe
  • 147(1):253-262
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-020-03334-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810639/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Objective!#!Isocitrate dehydrogenase (IDH)-wildtype glioblastomas are the most malignant glial tumours. Median survival is only 14-16 months after diagnosis, with patients aged ≥ 65 years reportedly showing worse outcome. This study aimed to further evaluate the prognostic role of age in a homogenously treated patient cohort.!##!Methods!#!The study includes 132 IDH-wildtype glioblastoma patients treated between 2013 and 2017 with open resection followed by radiotherapy with concomitant and maintenance temozolomide. Patients were dichotomized into a non-elderly (< 65 years) and an elderly (≥ 65 years) group. Extent of resection and the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status were determined for each tumour. Clinical and radiological follow-up data were obtained at 6 weeks after the end of radiation therapy and thereafter in 3-month intervals. Progression-free survival (PFS) and overall survival (OS) were evaluated in univariate and multivariate cox regression analyses.!##!Results!#!The elderly group consisted of 58 patients (median age: 70.5 years) and the non-elderly group of 74 patients (median age: 55 years). Median pre- and postoperative operative Karnofsky Performance Scale (KPS), Eastern Cooperative Oncology Group (ECOG) score and National Institutes of Stroke Scale (NIHSS) were not significantly different between the groups, but KPS and ECOG scores became significantly worse in the elderly group at 6 weeks after termination of radiation therapy. Neither PFS nor OS differed significantly between the age groups. Patients with MGMT promoter-methylated tumours survived longer.!##!Conclusion!#!Elderly patients in good pre- and postoperative clinical conditions may show similar outcome as younger patients when treated according to standard of care. However, elderly patients may suffer more frequently from clinical deterioration following chemoradiotherapy. In both age groups, MGMT promoter methylation was linked to longer PFS and OS.
1000 Sacherschließung
lokal Age Factors [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Chemoradiotherapy/mortality [MeSH]
lokal Original Article – Clinical Oncology
lokal Maintenance Chemotherapy/mortality [MeSH]
lokal Antineoplastic Agents, Alkylating/therapeutic use [MeSH]
lokal Glioblastoma/pathology [MeSH]
lokal Survival
lokal Male [MeSH]
lokal Brain Neoplasms/mortality [MeSH]
lokal Combined Modality Therapy [MeSH]
lokal Glioblastoma/genetics [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Mutation [MeSH]
lokal Age at diagnosis
lokal Brain Neoplasms/genetics [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Glioblastoma
lokal Glioblastoma/therapy [MeSH]
lokal Chemoradiotherapy
lokal Survival Rate [MeSH]
lokal Glioblastoma/mortality [MeSH]
lokal Biomarkers, Tumor/genetics [MeSH]
lokal Prognosis [MeSH]
lokal Young Adult [MeSH]
lokal Temozolomide/therapeutic use [MeSH]
lokal Isocitrate Dehydrogenase/genetics [MeSH]
lokal Brain Neoplasms/pathology [MeSH]
lokal Brain Neoplasms/therapy [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/QmVyZ2VyLCBLZXJzdGlu|https://frl.publisso.de/adhoc/uri/VHVyb3dza2ksIEJlcm5k|https://frl.publisso.de/adhoc/uri/RmVsc2JlcmcsIErDtnJn|https://frl.publisso.de/adhoc/uri/TWFsemtvcm4sIEJhc3RpYW4=|https://frl.publisso.de/adhoc/uri/UmVpZmVuYmVyZ2VyLCBHdWlkbw==|https://frl.publisso.de/adhoc/uri/U3RlaWdlciwgSGFucy1KYWtvYg==|https://frl.publisso.de/adhoc/uri/QnVkYWNoLCBXaWxmcmllZA==|https://frl.publisso.de/adhoc/uri/SGF1c3NtYW5uLCBKYW4=|https://frl.publisso.de/adhoc/uri/S25pcHBzLCBKb2hhbm5lcw==|https://frl.publisso.de/adhoc/uri/UmFwcCwgTWFyaW9u|https://frl.publisso.de/adhoc/uri/SMOkbmdnaSwgRGFuaWVs|https://frl.publisso.de/adhoc/uri/U2FiZWwsIE1pY2hhZWw=|https://orcid.org/0000-0002-9516-8257|https://orcid.org/0000-0002-1252-2944
1000 Hinweis
  • DeepGreen-ID: 3a167627bb8448d6bb010fb0a2dd330a ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6469376.rdf
1000 Erstellt am 2023-11-17T22:19:53.772+0100
1000 Erstellt von 322
1000 beschreibt frl:6469376
1000 Zuletzt bearbeitet 2023-12-01T09:43:29.908+0100
1000 Objekt bearb. Fri Dec 01 09:43:29 CET 2023
1000 Vgl. frl:6469376
1000 Oai Id
  1. oai:frl.publisso.de:frl:6469376 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source